A mechanism-first team working on a metabolic problem.
MetIQ was formed around a mechanism question, not a marketing one: if the receptor biology is well described in the literature, what would a non-drug system built strictly on that evidence look like? GLP-III is our first answer. Our MOF carrier work is a separate research track.
Scientific Advisory Board
The SAB reviews formulation rationale and every mechanism claim published under the MetIQ name. Seats are disclosed with affiliations and compensation status.
The patent-pending MOF platform
Separate research track. GLP-III does not use this carrier.
Metal-organic frameworks are crystalline lattices with tunable pore geometry. We are developing them as a protective carrier: actives held inside the lattice survive gastric transit and release on a pH and enzymatic cue rather than on a timer.
The platform is application-agnostic and pre-formulation. The filings cover the carrier itself, not any single product — and no MetIQ product on sale today relies on it.
Get the mechanism, not the marketing.
Launch dates, new articles, and Book Two progress. Roughly monthly, no drip sequences.
We send launch notices and new articles. No drip sequences.
Received — we'll be in touch.